131 related articles for article (PubMed ID: 12555361)
1. [Study of the efficacity and tolerance of diltiazem LP 300 mg in 2000 hypertensive patients (alone or combined with an angiotensin converting enzyme inhibitor].
Amar J; Joire JE; Salvador M
Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):69-75. PubMed ID: 12555361
[No Abstract] [Full Text] [Related]
2. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the tolerance and effectiveness of Diltiazem LP 300 mg in hypertensive patients with chronic renal insufficiency].
Bernadet-Monrozies P; Poilleux E; Suc JM
Ann Cardiol Angeiol (Paris); 1998 Oct; 47(8):589-94. PubMed ID: 9809145
[TBL] [Abstract][Full Text] [Related]
4. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
5. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. [The effect of acetylsalicylic acid on hypotensive action of enalapril in hypertensive patients].
Przewłocka-Kosmala M
Przegl Lek; 2002; 59(2):76-8. PubMed ID: 12152253
[TBL] [Abstract][Full Text] [Related]
8. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
Zheng S; Nath V; Coyne DW
Am J Nephrol; 2007; 27(5):522-9. PubMed ID: 17700014
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
[TBL] [Abstract][Full Text] [Related]
10. ACE inhibitor-based treatment and antihypertensive effects in patients with type 2 diabetes.
Jarmuzewska EA; Rocchi R; Guidoni A; Mangoni AA
Panminerva Med; 2008 Sep; 50(3):207-16. PubMed ID: 18927524
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
Bubbar CD; Blackburn DF; Wilson MP; Wilson TW
Ann Pharmacother; 2007 Jan; 41(1):129-32. PubMed ID: 17179189
[TBL] [Abstract][Full Text] [Related]
12. [New perspectives in the treatment of hypertension].
Mourad JJ
Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):76-9. PubMed ID: 12555362
[TBL] [Abstract][Full Text] [Related]
13. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
14. [Hypotensive effectiveness of therapy combined enalapril and nitrendipine and influence on the quality of life].
Bryl W; Cymerys M; Kujawska-Luczak M; Pupek-Musialik D
Pol Merkur Lekarski; 2005 Mar; 18(105):287-90. PubMed ID: 15997634
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.
Bisognano JD; Horwitz LD
West J Med; 1998 Apr; 168(4):272-4. PubMed ID: 9584674
[No Abstract] [Full Text] [Related]
16. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
18. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
Baer JT; Sauer WH; Berlin JA; Kimmel SE
Am J Cardiol; 2004 Aug; 94(4):479-81. PubMed ID: 15325933
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
